HRTX Heron Therapeutics, Inc.: רווח למניה ב-12 החודשים האחרונים

Heron Therapeutics (HRTX) is a pharmaceutical business developing oncology and pain management treatments that expands its product portfolio through patents without significantly increasing headcount. The company relies on third-party manufacturers, increasing deliveries to clinics to reduce unit promotion costs. This price chart shows EPS TTM at -46.50, as the firm competes for the hospital market by demonstrating the efficacy of its solutions.
HRTX (Heron Therapeutics Inc): פילוחים אנליטיים ודוחות לפי אינדיקטורים

This indicator calculates the percentage change in earnings per share over a rolling year, neutralizing seasonal reporting fluctuations. The metric reveals the actual balance between fundamental business growth and market speculation. For Heron Therapeutics (HRTX), which utilizes outsourced manufacturing, this calculation reflects cost management efficiency with minimal internal assets. By analyzing the rolling annual EPS change, an investor can distinguish a genuine trend reversal from random market noise.